The Peptide NewsroomPeptide research, industry and supply-chain headlines

Karnataka Regulators Cancel a Bengaluru Peptide Party as India's Longevity Market Accelerates

Topic card: skin-beauty

Karnataka's Food Safety and Drug Administration canceled a Bengaluru "Peptide Party" on August 29 and questioned its organizers, Upsurge Labs LLP, according to a report in The Indian Express on the country's fast-growing biohacking scene. Regulators asked about the ingredients in the products, the legality and safety of mixing them, and the truth behind claims of health benefits.

Peptides are short chains of the building blocks the body uses to carry out different tasks, and some are being sold or promoted as ways to encourage growth hormone release or repair damaged tissue. The report notes that many of those claims rest on early research, often in animals, rather than reliable studies in humans. Some of the compounds involved, it says, are bought online by makers posing as researchers.

Why the clinics are not regulated

The Express describes a grey market in which unapproved therapies are relabeled by premium aesthetic clinics as "elective wellness treatment" or "supplement cocktails," which sidesteps traditional drug approval. NAD+ infusions are the headline product, marketed as bypassing the gut to deliver the coenzyme straight into the bloodstream, though the report states scientists have yet to establish how much infused NAD+ reaches cells intact.

Dr Rashmi Sharma, a dermatologist at Fortis Vasant Kunj, describes "glow-up bars" offering pre-party vitamin and glutathione drips. The reporting is blunt about the payoff: there is little evidence that such injections reliably boost energy or improve youthful appearance.

A $7.53 billion forecast

Grand View Research estimated India's broad biohacking market at $1.21 billion in 2025, with a forecast of $7.53 billion by 2033. That growth lands alongside a demographic shift the report sets out plainly: people aged 60 and above are expected to make up 20.8 per cent of India's population by 2050, against 8.6 per cent in 2011.

Dr Prasun Chatterjee, president of the Indian Academy of Geriatrics, says peptide preparations raise questions about purity, impurities, dosing and how the body responds to substances not adequately studied for the intended use. His line is the sharpest in the piece: an ingredient's presence in the body does not establish that administering more of it will improve health.

Bottom line

A regulator asking an event organizer what is actually in the vials is the cheapest form of oversight available, and India now has one documented instance of it. What remains unsettled is whether any of these interventions do what the clinics selling them say.

Source: RSS.app — Peptides bundle. Read the original.

Filed under: skin-beauty, safety

Comments (0)

Discussion happens on Reddit.
Questions and corrections go to r/PeptideNewsroom.

Go to r/PeptideNewsroom

Corrections are the most useful thing you can post. Comments touching dosing, sourcing or links are held for a moderator first.

More from The Peptide Newsroom

Kemin Pitches Positive Aging, GLP-1 Support and Gut Health as Its 2027 Trends

Kemin's Filipa Quintela told Nutritional Outlook at SupplySide Global that positive aging, GLP-1 support through Slendesta, and gut health via the Gutopia platform will shape the supplier's 2027 development. She also put American lutein intake at around 2 mg a day against an optimal 10 mg.

Ingredient Supplier Kemin Puts GLP-1 Companion Nutrition at the Center of Its 2027 Outlook

At SupplySide Global, ingredient developer Kemin outlined a 2027 wellness outlook built on GLP-1 companion nutrition, gut health, and positive aging, with FloraGLO Lutein repositioned toward cognition. No trial data or outcome figures appear anywhere in the coverage, which makes this a supplier forecast rather than new evidence.

Engineered ICOSL Peptide Cuts Proteinuria in Mice, But No Human Trials Yet

Researchers engineered a 19-amino-acid peptide from inducible co-stimulator ligand that blocks alpha-v-beta-3 integrin on kidney podocytes, reducing urinary protein across several rodent models. The work is entirely preclinical, tested a single dose, and human trials have not begun.